Science

Praveen Kumar Marimuthu: RWD Shows NACT Plus Immunotherapy Nearly Doubles pCR in MIBC

Praveen Kumar Marimuthu/LinkedIn

May 29, 2025, 17:28

Praveen Kumar Marimuthu: RWD Shows NACT Plus Immunotherapy Nearly Doubles pCR in MIBC

Praveen Kumar Marimuthu, Assistant Professor of Medical Oncology at Christian Medical College and Hospital, shared a post on X about a paper by Xinjia Ding et al. published in Scientific Reports:

“Real-world data in Muscle invasive bladder cancer shows that NACT plus immunotherapy (Tislelizumab/pembro) nearly doubled pCR vs chemo alone (48.3% vs 25.4%) and improved downstaging (76% vs 48%).”

Title: Real-world comparison of neoadjuvant chemoimmunotherapy and chemotherapy in muscle-invasive bladder cancer

Authors: Xinjia Ding, Chao Liu, Xiaohui Li, Zhigao Wang, Yanping Wu, Yi Song, Wei Yu, Shikai Wu

You can read the Full Article in Scientific Reports.

More posts featuring Praveen Kumar Marimuthu.

bladder cancer cancer Chao Liu immunotherapy MIBC muscle invasive bladder cancer NACT OncoDaily Oncology Praveen Kumar Marimuthu Shikai Wu Wei Yu Xiaohui Li Xinjia Ding Yanping Wu Yi Song Zhigao Wang

Cardio-Oncology in Focus: How Chemotherapy Can Harm Heart Health

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect